So it's possible that utrm could be hit with a crippling gsk judgement and further, by a decision in the dillingham case that will also require utrm to pay through the nose?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.